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Abstract
Endocrine therapy is a cornerstone of medical treatment for estrogen receptorepositive breast cancer. The discovery
of selective estrogen receptor modulators (SERMs) > 40 years ago represented a revolutionary advance in the
treatment of breast cancer. As a therapeutic class, SERMs have either estrogenic or antiestrogenic activity, depending
on the target tissue and the hormonal environment. In breast tissue, SERMs are antiestrogenic, making them a major
treatment option for women with hormone-sensitive breast cancer. Toremifene citrate was developed > 20 years ago
with the goal of achieving efﬁcacy similar to that of tamoxifen and with an improved safety proﬁle. Although studies to
date have not conﬁrmed a clear safety advantage or disadvantage for toremifene, clinical data support the efﬁcacy and
safety of toremifene for the treatment of breast cancer in postmenopausal patients. Toremifene also has a pharma-
cokinetic proﬁle and metabolic pathway different from that of tamoxifen, which may provide a therapeutic advantage in
certain patients. In addition, because of the selective estrogenic effects of SERMs in bone and on lipid levels along
with a different side effect proﬁle compared with the aromatase inhibitors (AIs), toremifene is a viable option to the AIs
for some patients. Despite a number of clinical trials and over 500,000 patient years of use, many oncologists have
limited familiarity with toremifene data. This article will examine the rationale for the use of toremifene in the treatment
of women with breast cancer and review data from 20 years of clinical experience with this agent.
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Breast cancer is the leading cause of cancer in women, accounting
for an estimated 28% of new cancers.1 The American Cancer Society
estimates that 232,340 new cases of female breast cancer will be
diagnosed and 39,620womenwill die of breast cancer in 2013.1 Early
detection and more effective treatment regimens have improved
5-year survival rates, resulting in a population of approximately 2.5
million women in the United States living with breast cancer.2
Treatment of breast cancer is at the forefront of the trend toward
personalized medicine. Examination of tumor samples for the
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Open access under CC BY-NCassessing the extent of disease and the risk of recurrence and in
predicting response to treatment. Genetic information, such as the
presence of the breast cancer genes 1 and 2 (BRCA1 and BRCA2), is
used to assess breast cancer risk and to guide surveillance and pre-
vention strategies.3,4 Additionally, the estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2) are considered critical diagnostic biomarkers for
all newly diagnosed invasive breast cancers, according to the Na-
tional Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines for breast cancer.3 The tailoring of medical treatment to
the individual characteristics of a patient has recently been extended
to include assessment of multigene proﬁles that may inﬂuence
a patient’s response to a particular therapy, as exempliﬁed by
Oncotype DX, MammaPrint, and others.5,6 This topic has been the
subject of comprehensive review articles.7-10
Genetic testing is also increasingly used to assess an individual
patient’s ability to effectively metabolize medications.4 Genetic
polymorphisms in metabolism may result in increased toxicity or
decreased efﬁcacy of both parent drugs and their metabolites. Ge-
netic tests are now widely available for patients who are taking
certain prescription medications, such as clopidogrel and warfarin.11
Recognition of the impact of genetic differences in drug meta-
bolism has motivated clinicians to take a new look at anotherClinical Breast Cancer February 2014 - 1-ND license.
Table 1 Baseline Characteristics in Toremifene Pivotal Trials in Postmenopausal Women With Metastatic Breast Cancer
Study
North American Eastern European Nordic
TOR60
n [ 221
TAM20
n [ 215
TOR60
n [ 157
TAM40
n [ 149
TOR60
n [ 214
TAM40
n [ 201
Median age, years  SD (range) 61  11 (35-85) 63  10 (37-88) 61  9.3 (31-90) 62  8.3 (38-85) 66  9.4 (45-90) 66  10.4 (34-88)
White, % 84 86 10 100 100 100
ER-, % 10 6 19 24 20 22
ER status unknown, % 30 27 66 66 42 43
Prior hormonal therapy, % NR NR 7.0 7.4 6.1 8.5
Dominant site
Visceral, % 39 38 29 30 28 31
Bone, % 45 45 17 23 32 35
Soft tissue, % 16 16 53 46 39 32%
Data sources: Coezy E, et al.,22 Wiebe VJ, et al.,23 and Kelly CM, Pritchard KI.24
Abbreviations: ER ¼ estrogen receptor; NR ¼ not reported; TAM ¼ tamoxifen; TAM20 ¼ tamoxifen 20 mg; TAM40 = tamoxifen 40 mg; TOR ¼ toremifene; TOR 60 ¼ toremifene 60 mg.
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Inc, Bridgewater, NJ), as an option for the treatment of breast
cancer in certain patient groups. Toremifene citrate differs in
structure from tamoxifen by only 1 chlorine atom. Toremifene has
been marketed in Finland since 1988 and was approved for use in
the United States in 1997 for the treatment of metastatic breast
cancer in postmenopausal women with ER positive (ERþ) or
tumors of unknown ER status.12 Toremifene’s in vitro efﬁcacy, as
measured by binding of toremifene to ERs and growth inhibitory
effects on Michigan Cancer Foundation (MCF) human cancer cells,
is similar to that of tamoxifen.13,14 However, 2 metabolites of
tamoxifen, 4-hydroxyl-tamoxifen and 4-hydroxyl-N-desmethyl-
tamoxifen (endoxifen), are more potent in binding the ER and
inhibiting MCF cell growth than the parent compound.15
Tamoxifen is thus frequently referred to as a prodrug and plasma
concentrations of tamoxifen and its metabolites have been shown to
be signiﬁcantly altered in patients with different CYP2D6 geno-
types.15-18 Additionally, concomitant use of potent CYP2D6 in-
hibitors and tamoxifen result in alterations in serum plasma
concentrations of both tamoxifen and its active metabolites.15,19 In
contrast, toremifene is not a prodrug and does not require enzy-
matic conversion by cytochrome P450 enzymes, such as CYP2D6,
for activity.20 There has been considerable discussion and debate
regarding the clinical sequelae of these alterations.16,21-24 Two
recent subset analyses, from the Breast International Group (BIG)
1-98 and Arimidex, Tamoxifen, Alone or in Combination (ATAC)
studies, cast signiﬁcant questions on the clinical applicability of
testing for CYP2D6 polymorphisms in patients treated with
tamoxifen.25,26 Subsequent challenges to the BIG 1-98 and ATAC
conclusions have centered on concerns regarding the retrospective
nature of the pharmacogenomics analyses and on large deviations
from Hardy-Weinberg equilibrium in their results.27 In contrast, a
third recent study, The Austrian Breast and Colorectal Cancer
Study Group Trial 8 (ABCSG-8), found an association between
CYP2D6 polymorphisms and cancer recurrence during the ﬁrst 5
years of tamoxifen therapy but no association when women had
been switched to anastrozole after 2 years of tamoxifen therapy.28
These conﬂicting results in 3 recently reported studies highlight
the controversy surrounding CYP2D6 polymorphisms and outcomenical Breast Cancer February 2014with tamoxifen. A detailed analysis of the CYP2D6 controversy goes
beyond the scope of our review but has been discussed in depth by
others.27,29,30 Because of the controversial but potential issues of
impaired metabolism and drug interactions, tamoxifen may be a less
appealing SERM than toremifene in certain patients with breast
cancer.
Toremifene Efﬁcacy in Breast
Cancer
Postmenopausal Women With Metastatic Breast Cancer
Toremifene is indicated for the treatment of metastatic breast
cancer in postmenopausal women with ERþ or ER unknown
tumors.12 Three prospective, randomized, controlled clinical studies
were conducted to evaluate the efﬁcacy and safety of toremifene for
the treatment of metastatic breast cancer in postmenopausal women
who had ERþ or ER unknown tumors.31-33 The North American
trial randomized patients to parallel groups receiving toremifene 60
mg or tamoxifen 20 mg.32 Both the Eastern European and the
Nordic studies randomized patients to toremifene 60 mg or
tamoxifen 40 mg (a dose commonly used outside of the United
States).31,33 In addition to these randomizations, there were high-
dose toremifene groups in 2 trials (toremifene 200 mg in the
North American study and 240 mg in the Easter European study).
Because these doses provided no additional beneﬁt over the 60 mg
dose, no further details will be provided here but are available in the
original publications.31,33 The North American study included both
perimenopausal and postmenopausal patients with metastatic breast
cancer, whereas the Eastern European and Nordic studies included
only postmenopausal women. In all 3 studies, patients had at least 1
measurable or evaluable lesion, the majority of which were in the
liver, lungs, or bone. Baseline characteristics are listed in Table 1.
Primary efﬁcacy variables were response rate (RR) and time to
progression (TTP). Survival was also evaluated. Additionally, 95%
conﬁdence intervals (95% CIs) were calculated for the difference in
RR between groups and the hazard ratio (relative risk was calculated
for an unfavorable event, such as disease progression or death)
between groups for TTP and survival. Of the 3 studies, 2 demon-
strated similar results for all efﬁcacy endpoints.31,32 The Nordic
study showed a longer TTP for tamoxifen (Table 2).33
Table 2 Toremifene Treatment for Metastatic Breast Cancer: Comparisons With Tamoxifen Treatment
Study
North American32 Eastern European31 Nordic33
TOR60
n [ 221
TAM20
n [ 215
TOR60
n [ 157
TAM40
n [ 149
TOR60
n [ 214
TAM40
n [ 201
Response
CR þ PR 14 þ 33 11 þ 30 7 þ 25 3 þ 28 19 þ 48 19 þ 56
RR (CR þ PR), % 21.3 19.1 20.4 20.8 31.3 37.3
Difference in RR 2.2 0.4 6.0
95% CI for difference in RR 5.8 to 10.2 9.5 to 8.6 15.1 to 3.1
Time to Progression
Median TTP, mo 5.6 5.8 4.9 5.0 7.3 10.2
Hazard ratio, TAM/TOR 1.01 1.02 0.80
95% CI for hazard ratio, % 0.81-1.26 0.79-1.31 0.64-1.00
Survival
Median survival, mo 33.6 34.0 25.4 23.4 33.0 38.7
Hazard ratio, TAM/TOR 0.94 0.96 0.94
95% CI for hazard ratio, % 0.74 to 1.24 0.72 to 1.28 0.73 to 1.22
Data sources: Hayes DF, et al.,32 Gershanovich M, et al.,31 Pyrhonen S, et al.33
Abbreviations: CR ¼ complete response; PR ¼ partial response; RR ¼ response rate; TAM ¼ tamoxifen; TOR¼ toremifene; TTP ¼ time to progression.
The North American and Eastern European studies also included high-dose toremifene arms of 200 and 240 mg daily, respectively. The high-dose groups, toremifene 200 mg daily in the North
American Study and 240 mg daily in the Eastern European Study, were not superior to the lower toremifene dose groups.
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Four studies evaluated the efﬁcacy of toremifene vs. tamoxifen in
postmenopausal women for the adjuvant treatment of breast cancer.
These studies were conducted by the International Breast Cancer
Study Group (IBCSG)(2 separate trials with pooled results) in the
mid 1990s, the Finnish Breast Cancer Group (FBCG) in the late
1990s, and North American Fareston vs. Tamoxifen Adjuvant Trial
(NAFTA) in early 2000 (Table 3).34-36
IBCSG conducted 2 randomized trials (Trial 12-93 and Trial
14-93) comparing toremifene 60 mg daily with tamoxifen 20 mg
daily as adjuvant medications with chemotherapy in perimenopausal
and postmenopausal women with node positive breast cancer.35
Trial 12-93 compared 3 adjuvant chemotherapy regimens (4 cour-
ses of anthracycline [doxorubicin or epirubicin] plus cyclophos-
phamide [AC]), initiating endocrine therapy concurrently or
sequentially or using endocrine therapy alone. Each of the treatment
arms included either toremifene or tamoxifen. Trial 14-93
compared 2 regimens of adjunctive chemotherapy (AC for 4 rounds
followed by CMF [cyclophosphamide, methotrexate, and ﬂuoro-
uracil] for 3 rounds) with and without a 16-week gap betweenTable 3 Adjuvant Studies of Toremifene in Postmenopausal Women
Study Stage
Menopausal
Status Total n
TOR mg/
Leng
Treat
IBCSG35 Node positive Peri/post 1035 60/20,
Finnish34,37,38 Node positive Post 1480 40/20,
NAFTA36 I-II Peri/post 1813 60/20,
Meta-analysis38
Abbreviations: DFS ¼ disease-free survival; IBCSG ¼ International Breast Cancer Study Group; NAFT
survival; RR ¼ response rate; TAM ¼ tamoxifen; TOR¼ toremifene.chemotherapy rounds. Results from both trials were pooled for
analysis (n ¼ 1035). The 5-year disease-free survival (DFS) and
overall survival (OS) were similar for both toremifene and tamoxifen
(DFS: 72% toremifene, 69% tamoxifen; OS: 85% toremifene, 81%
tamoxifen). In those patients with ERþ tumors (n ¼ 773), tor-
emifene demonstrated a 5-year DFS of 76% compared with 72%
for tamoxifen. The 5-year OS for patients with ERþ tumors with
toremifene and tamoxifen were 90% and 86%, respectively.35
The FBCG study compared toremifene 40 mg daily with
tamoxifen 20 mg daily for 3 years to evaluate DFS and OS.34,37
Postmenopausal women (n ¼ 1480) with node-positive invasive
breast cancer were followed for a mean of 4.4 years. The majority of
patients were ERþ (n ¼ 1153). There was no signiﬁcant difference
for OS between the 2 groups.37
The NAFTA trial evaluated patients with hormone receptor
(HR)epositive breast cancer (n ¼ 1813) and randomized them to
toremifene 60 mg or tamoxifen 20 mg daily for 5 years. Eligible
patients included perimenopausal and postmenopausal women with
a diagnosis of American Joint Committee on Cancer (AJCC) stage I
or II HRþ primary invasive breast cancer. Patients were required toWith Breast Cancer
TAM mg,
th of
ment
Follow-up,
years
DFS
RR (95% CI)
OS
RR (95% CI)
5 years 5.5 0.95 (0.76-1.18) 1.03 (0.78-1.36)
3 years 4.4 NR 1.07 (0.91-1.27)
5 years 5 1.04 (0.72-1.49) 0.95 (0.62-1.45)
1.05 (0.95-1.17)
P ¼ .431
1.07 (0.97-1.19)
P ¼ .994
A ¼ North American Fareston vs. Tamoxifen Adjuvant Trial; NR ¼ not reported; OS ¼ overall
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Table 4 Toremifene for Metastatic Breast Cancer: Comparisons With Tamoxifen and Letrozole1
TOR60
n[115
TOR240
n[106
TAM20
n[117
LET2.5
n[113
Objective response, n (%) 38 (33) 44 (41) 30 (26)a 40 (35)
Stabilization, n (%) 57 (50) 58 (55) 54 (46)a 59 (52)
Progression, n (%) 20 (17) 4 (4) 33 (28)a 14 (12)
Subjective response, n (%) 80 (70) 85 (80) 74 (63)a 82 (73)
Median duration of remission 12.1 months 13.3 months 8.6 months 12.8 months
Data Source: Zeynalov et al.,39
Abbreviations: LET2.5 ¼ letrozole 2.5 mg; TAM20 ¼ tamoxifen 20 mg; TOR240 ¼ toremifene 240 mg; TOR60 ¼ toremifene 60 mg.
aP < .05 compared to TOR60, TOR240 and LET2.5.
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node staging within 12 weeks of initiating adjuvant systemic or
radiation therapy. Adjuvant systemic therapy with chemotherapy
was permitted. After a median follow-up of 59 months, 5-year
actuarial DFS and OS were not signiﬁcantly different (DFS ¼
91.2% for both compounds; OS 93.7% and 92.7% for toremifene
and tamoxifen , respectively).36
A meta-analysis of prospective studies of adjuvant toremifene
involving data from 3709 women found no difference in overall
survival (RR ¼ 1.07; 95% CI, 0.97-1.19; P ¼ .99) or disease free
survival (RR ¼ 1.05; 95% CI, 0.95-1.17; P ¼ .43) between tor-
emifene and tamoxifen (Table 3). The authors concluded that
toremifene and tamoxifen were equally effective in the adjuvant
setting for both perimenopausal and postmenopausal women.38
Toremifene vs. Aromatase Inhibitors and After
Aromatase-Inhibitor Failure
In clinical trials in metastatic disease, toremifene has shown equal
efﬁcacy to the aromatase inhibitors (AIs) when given alone34 or in
combination with AI therapy.39,40 In 1 study as monotherapy,
2 toremifene doses, 60 mg and 240 mg, were compared with
tamoxifen 20 mg and with letrozole 2.5 mg (Femara, Novartis, East
Hanover, NJ) treatment in 451 postmenopausal women with
disseminated breast cancer.39 The majority of the patients studied
were ERþPRþ, ERþPR-, or ER-PRþ; however, approximately 30%
of patients were ER-PR-. Response, disease progression, and dura-
tion of remission were similar for toremifene 60 mg daily and
letrozole 2.5 mg daily for all endpoints. Both toremifene 60 mg and
letrozole 2.5 mg showed superior efﬁcacy to tamoxifen 20 mg daily
(P < .05) (Table 4).39 Because all the patients in this study had
received adjuvant hormonal therapy with tamoxifen for treatment of
their primary tumor, the apparent superiority of both toremifene
and letrozole over tamoxifen is not surprising. However, the simi-
larity in efﬁcacy between toremifene and letrozole is intriguing.
Efﬁcacy was similar in each of the treatment groups regardless of the
receptor status.
A randomized, double-blind trial of 865 women with metastatic
disease evaluated toremifene 60 mg daily in combination with the
AI, atamestane 500 mg daily, vs. monotherapy with letrozole
2.5 mg daily.40 Unlike the ATAC trial, which reported that the
addition of tamoxifen to anastrozole was inferior to anastrozole
monotherapy as adjuvant treatment,41 this study found that addi-
tion of toremifene to an AI for metastatic disease neither reduced
the efﬁcacy of the AI nor resulted in worse safety and tolerability ofnical Breast Cancer February 2014the AI.40 Overall response (complete response þ partial response)
and clinical beneﬁt were not statistically different between the
2 treatment arms. Median time to progression (TTP) was the same
for both groups (11.2 mo).40
There is also indication that high-dose toremifene (120 mg daily)
may be effective and safe following AI failure. The prospective
High-Dose Toremifene (Fareston) for Patients With Aromatase
InhibitoreResistant Tumor (Hi-FAIR) Phase II trial compared
toremifene 120 mg with exemestane 25 mg in 91 patients for whom
treatment with a nonsteroidal AI had failed.42 After a median
16.9-month observation period, interim results indicate a signiﬁ-
cantly higher clinical beneﬁt rate (complete response, partial
response, or stable disease > 6 mo) (47.5% for toremifene 120mg
vs. 27% for exemestane; P ¼ .046) and progression-free survival
(hazard ratio ¼ 0.62; 95% CI, 0.38-0.99; P ¼ .047) with tor-
emifene 120mg than with exemestane, but no difference in OS.
Both treatments were equally well tolerated, with no reported severe
adverse event. A second, prospective, multicenter study examined
toremifene 120 mg daily in hormone-responsive postmenopausal
women who had received adjuvant AI therapy postoperatively for >
1 year and had relapsed during the treatment or within 12 months
of completion of adjuvant therapy.43 Because of the difﬁculty with
accrual, only 13 patients were enrolled in this study; however, the
authors report 1 patient with partial response (7.7%) and 5 patients
(38.5%) with stable disease > 6 months, for a clinical beneﬁt rate of
46.2% with toremifene 120 mg.43 In addition, Yamamoto et al.
retrospectively evaluated the effect of toremifene 120 mg day for the
treatment of breast cancer in 83 women who relapsed on AIs.44 Of
these 83 patients, 12 patients (15%) achieved partial response and
24 patients (30%) had stable disease for 24 weeks, demonstrating
clinical beneﬁt in 45% of patients.44
Efﬁcacy in Tamoxifen-Resistant Breast Cancer
The literature on toremifene in tamoxifen-resistant patients was
last reviewed in 1998.45 Vogel et al. investigated the effect of tor-
emifene 200 mg daily in a phase II clinical trial in patients
(total n ¼ 102) with advanced breast cancer who had failed to
respond to tamoxifen or who experienced disease progression on
tamoxifen.46 Of these, 28 patients had primary refractory disease,
43 patients had relapsed after prior tamoxifen response, and 31
patients had relapsed while receiving tamoxifen adjuvant treatment.
Both perimenopausal and postmenopausal women were included.
The objective response rate was 5% (95% [CI], 3-7). Median time
to treatment failure (TTF) was 10.9 months for the 5 responders.
Charles L. Vogel et alAn additional 23 patients (23%) had stable disease for a median
TTF of 7.8 months, whereas the patients who experienced treat-
ment failure had a median TTF of 2.1 months. Since that time, it
has been recognized that prolonged stable disease greater than 6
months represents a useful outcome, with survival equaling that of
responding patients. Consequently, a reanalysis of this study was
conducted to evaluate the impact of stable disease in these pa-
tients.47 In all, 19 patients had complete response, partial response,
or stable disease > 6 months, for a clinical beneﬁt rate of 18% (95%
CI, 11%-26%). Clinical beneﬁt occurred in all 3 categories of pa-
tients with tamoxifen-refractory breast cancer entered into this trial.
Although the median survival in those with clinical beneﬁt or no
response was not reached at the time of data cutoff, the log-rank
statistic showed signiﬁcantly better survival in those with clinical
beneﬁt (P ¼ .02). These data are similar to those published by
Asaishi et al.48 Further, in 2002 Gams presented a summary of
efﬁcacy data from several trials using higher than standard (60 mg
daily) doses of toremifene.49 In the ﬁrst group of studies, 366
women who progressed while receiving tamoxifen were treated in 9
separate trials with doses of toremifene ranging from 120 to 240 mg
daily. Of these patients, 37 (10.1%) achieved an objective response,
whereas an additional 60 (16.4%) achieved prolonged stable disease
for a clinical beneﬁt rate of 26.5%. In another group of studies, 146
women with advanced breast cancer resistant to tamoxifen were
treated with additional treatment modalities, including cytotoxic
agents prior to toremifene therapy. In this third-line setting, there
were 17 (11.6%) objective responses and 35 (24.0%) patients with
prolonged stable disease, producing an overall clinical beneﬁt of
35.6%. The toxicity experienced by patients in these studies was
similar to that observed with conventional doses of tamoxifen or
toremifene.
Premenopausal Women
Clinical data regarding the use of toremifene for the treatment of
breast cancer in premenopausal women are limited. A phase II trial
(n ¼ 134) of toremifene at various doses conducted in patients with
primary or advanced recurrent breast cancer patients included 31
(23%) premenopausal women.46 Unfortunately, data were not
analyzed based on menopausal status. A registry study from Korea
examined survival outcomes in young (age  50 y) HRþ breast
cancer patients given adjuvant hormone therapy after chemo-
therapy. Of the 3489 patients known to have received adjuvant
hormonal therapy, 2856 (82%) had received tamoxifen and 632
(18%) had received toremifene, but survival data were not reported
based on speciﬁc SERM.50
A retrospective cohort-based study of toremifene performed in
China in premenopausal women with HRþ early invasive breast
cancer compared premenopausal women who had received tor-
emifene (n ¼ 212) with those who had received tamoxifen
(n ¼ 240).51 How toremifene was chosen as a treatment option in
212 premenopausal women in the absence of published phase II or
III clinical trials in premenopausal women either as adjuvant or in
the metastatic setting remains a subject of speculation. Regardless,
after a mean follow-up of 57.3 months (range, 17.3 to 209 mo),
toremifene and tamoxifen resulted in 5-year OS rates of 100% and
98.4%, respectively. Recurrence-free survival was signiﬁcantly
greater with toremifene (97.2% compared with 90.4% withtamoxifen; P ¼ .022).51 Toxicity was similar in the 2 groups, with
no woman experiencing a severe complication such as a thrombo-
embolic or cerebrovascular event. Hot ﬂashes were the only side
effect signiﬁcantly different between groups and were reported more
frequently with toremifene.
Two additional studies involving the use of toremifene for pre-
menstrual mastalgia and for effects on bone mineral density (BMD)
contribute to the safety experience in premenopausal women. In
a crossover study of 62 patients with premenstrual mastalgia, pa-
tients were randomized to toremifene 20 mg daily or placebo from
day 15 of the menstrual cycle until menstruation for 3 cycles. After
the third cycle, patients crossed over to receive either toremifene 20
mg or placebo for an additional 3 cycles. The primary outcome
measure was cyclic breast pain relief assessed by visual analogue scale
(VAS) score. Toremifene-treated patients experienced greater re-
ductions in pain scores than the placebo group (P ¼ .004). Re-
ported side effects included headache and nausea but no hot
ﬂashes.52
An additional randomized, double-blind, placebo-controlled
study assessed the percent change in BMD at the lumbar spine and
proximal femoral neck in both premenopausal and postmenopausal
women at high risk for developing breast cancer (n ¼ 259).53
Patients were randomized to toremifene 60 mg daily, tamoxifen
20 mg daily, or placebo. Premenopausal women treated with tor-
emifene 60 mg (n ¼ 35) or placebo (n ¼ 37) daily reported
menopausal symptoms (18.3% toremifene vs. 5.3% placebo),
weight increase (19.1% toremifene vs. 12.3% placebo) or hot
ﬂushes (17.4% toremifene vs. 7.9% placebo).53 BMD effects in this
trial will be discussed in a later section of this review.
Toremifene Safety
Safety data for toremifene are derived from a number of clinical
trials and over 500,000 patient-years of total clinical experience.
The North American metastatic disease clinical trial prospectively
assessed 8 toxicities considered to be drug related and compared the
rates of occurrence for toremifene and tamoxifen. Prospectively
assessed adverse events included hot ﬂashes (35%), sweating (20%),
nausea (14%), vaginal discharge (13%), dizziness (9%), edema
(5%), vomiting (4%) and vaginal bleeding (2%), and were similar
between treatment arms (Table 5).22 Data from the 3 pivotal trials
conducted in postmenopausal women with metastatic breast cancer
demonstrated no signiﬁcant difference in serious adverse events
(Table 6), and approximately 1% of patients receiving toremifene or
tamoxifen discontinued treatment as a result of adverse events.31-33
As observed with tamoxifen,54 ocular abnormalities were observed
in all 3 trials with toremifene, but only the Nordic trial found
a signiﬁcant difference in cataracts between the toremifene and
tamoxifen groups (0% with toremifene and 2.5% with tamoxifen;
P ¼ .026). 31-33
Cardiovascular Events
Estrogens have been associated with various degrees of QT in-
terval prolongation.55 While a formal, thorough QT study has never
been conducted for tamoxifen, prolongation of the QT interval has
been reported.54,56,57 A thorough QT study conducted in men
showed that toremifene prolongs the QTc interval in a dose- and
concentration-related manner. Toremifene should not be prescribedClinical Breast Cancer February 2014 - 5
Table 5 Prospectively Assessed Adverse Events From the
North American Study of Toremifene
Adverse Events
North American Study
TOR60
n [ 221
TAM20
n [ 215
Hot ﬂashes, % 35 30
Sweating, % 20 17
Nausea, % 14 15
Vaginal discharge, % 13 16
Dizziness, % 9 7
Edema, % 5 5
Vomiting, % 4 2
Vaginal bleeding, % 2 4
Data source: Fareston [package insert].12
Abbreviations: TAM20 ¼ tamoxifen 20 mg; TOR60 ¼ toremifene 60 mg.
Toremifene in Breast Cancer
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rected hypokalemia, or uncorrected hypomagnesemia.12
Thromboembolic Events
It has been well established that administration of estrogenic
agents confers an increased risk of venous thromboembolic events
(VTE) in patients. VTEs have also been observed in patients treated
with SERMs. In the 3 pivotal studies comparing toremifene and
tamoxifen the VTE rates were 3.3% and 3.4%, respectively.
Therefore, it is recommended that patients with a history of
thromboembolic diseases should generally not be treated with
SERMs, including toremifene, tamoxifen, and raloxifene.12
Risk of Endometrial Cancer
In a National Surgical Adjuvant Breast and Bowel Project placebo-
controlled study of tamoxifen, of 2843 patients with node-negative,
ERþ invasive breast cancer, the average annual hazard rate of devel-
oping endometrial cancer within the ﬁrst 5 years of follow-up was 1.2
per 1000 patient-years for tamoxifen.58 Most toremifene trials haveTable 6 Toremifene Treatment for Metastatic Breast Cancer: Seriou
Serious Adverse
Events
North American32
TOR60
n [ 221 (%)
TAM20
n [ 215 (%) n [
Thrombophlebitis, n (%) 4 (2) 2 (1)
Thrombosis, n (%) e 2 (1)
CVA/TIA, n (%) e 1 (<1)
Pulmonary embolism, n (%) 1 (<1) e
Cardiac failure, n (%) 2 (1) 1 (<1)
Myocardial infarction, n (%) 2 (1) 3 (1.5)
Arrhythmia, n (%) e e
Angina pectoris, n (%) e e
Cataracts, n (%) 22 (10) 16 (7.5)
Elevated SGOT, n (%) 11 (5) 2 (1)
Elevated alkaline phosphatase, n (%) 41 (19) 24 (11)
Elevated bilirubin, n (%) 3 (1.5) 4 (2)
Data sources: Hayes DF, et al.,32 Gershanovich M, et al.,31 Pyrhonen S, et al.33
Abbreviations: CVA ¼ cerebrovascular event; SGOT ¼ serum glutamate oxaloacetate transaminase
TOR60 ¼ toremifene 60 mg.
nical Breast Cancer February 2014been conducted in patients with metastatic disease; therefore,
extensive data on the potential endometrial tumorigenicity of long-
term treatment with toremifene are not available. There have been
reports of endometrial cancer with toremifene; however, limitations
including short duration of treatment, prior antiestrogen treatment
(eg, tamoxifen treatment), or premalignant conditions make it
difﬁcult to establish the causal role of toremifene. A population-based
case-control study evaluated the risk of endometrial cancer related to
tamoxifen or toremifene treatment.59 Patients with a breast cancer
diagnosis since 1980 in Finland who subsequently developed endo-
metrial cancer by the end of 1995 and 3 matched controls were
identiﬁed among the 38,000 breast cancer patients of the Finnish
Cancer Registry database. Detailed information on the treatment of
breast cancer and potential confounders was collected from hospital
records. Unfortunately, the total number of patients given tamoxifen
and toremifene was not provided. The primary outcome of the study
was the risk of subsequent endometrial cancer among breast cancer
patients, and 144 cases of endometrial cancer and 368 controls were
identiﬁed. Of the 144 cases of endometrial cancer, 59 had received
tamoxifen and 3 had received toremifene. The odds ratio (OR) for
tamoxifen treatment, adjusted for signiﬁcant cofactors (increased risk
associated with obesity, low parity, and PR positivity) was 2.9 (95%
CI, 1.8-4.7). The adjusted OR for toremifene, based only on 3 cases
and 6 controls, was 0.8 (95%CI, 0.2-3.8). None of the cases and only
1 control had received toremifene for  5 years before the study
closed. Because of the small number of patients receiving toremifene,
the risk of developing endometrial cancer was inconclusive.59
Because thromboembolic and uterine side effects of SERMs are
considered the most serious, Zhou and colleagues analyzed these
events in a safety meta-analysis of prospective adjuvant trials of
toremifene and tamoxifen (Fig. 1).38 Their analysis found rates of
deep vein thrombosis, cerebrovascular accident, pulmonary embo-
lism, and thromboembolic events with toremifene similar to those
with tamoxifen.38 In addition, the rates of endometrial polyps and
the incidence of endometrial cancer were almost the same for both
groups (Fig. 1).s Adverse Events
Eastern European31 Nordic33
TOR60
157 (%)
TAM40
n [ 149 (%)
TOR60
n [ 214 (%)
TAM40
n [ 201 (%)
1 (<1) e e 1 (<1)
1 (<1) 1 (<1) 4 (2) 3 (1.5)
1 (<1) e 3 (1.5) 4 (2)
1 (<1) 1 (<1) 4 (2) 4 (2)
e 1 (<1) 2 (1) 3 (1.5)
1 (<1) 2 (1) e 1 (<1)
e e 3 (1.5) 1 (<1)
1 (<1) e 1 (<1) 2 (1)
e e e 5 (3)
30 (19) 22 (15) 32 (15) 35 (17)
16 (10) 13 (9) 18 (8) 31 (15)
2 (1) 1 (<1) 2 (1) 3 (1.5)
; TAM20 ¼ tamoxifen 20 mg; TAM40 ¼ tamoxifen 40 mg; TIA ¼ transient ischemic attack;
Figure 1 Meta-Analysis of Thromboembolic and Gynecologic Events in Patients Treated With Toremifene Compared With Patients
Treated With Tamoxifen in an Adjuvant Setting. Forest Plots for Meta Analysis of (A) Thromboembolic Events and (B)
Gynecologic Events in Patients Treated With Toremifene Compared With Those Treated With Tamoxifen in an Adjuvant Setting
Adapted with permission from Zhou WB, et al. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer
Res Treat 2011; 128:625-31.38
Charles L. Vogel et alSerum Lipid Parameters
In general, both tamoxifen and toremifene appear to have
a positive effect on the lipid proﬁle.60,61 In a comparative study
following 12 months of therapy with either SERM (tamoxifen,
n ¼ 121; toremifene, n ¼ 76), total cholesterol levels had signiﬁ-
cantly decreased in both groups (P < .001), high-density lipopro-
tein levels signiﬁcantly decreased in the tamoxifen group (P < .001)
but signiﬁcantly increased in the toremifene group (P < .001), and
triglyceride levels signiﬁcantly increased in the tamoxifen group
(P < .001) but signiﬁcantly decreased in the toremifene group
(P < .001). Calculated low-density lipoprotein concentration
changed from 137.5 mg/dL to 122.9 mg/dL for tamoxifen and from
140.5 mg/dL to 128.8 mg/dL for toremifene.60
BMD
Two studies have assessed the effects of toremifene on BMD in
women. Marttunen et al compared the effects on BMD of tamoxifen
20 mg to those of toremifene 40 mg daily in 30 postmenopausal
patients with breast cancer.62 Tamoxifen increased BMD by 2% in
the lumbar spine, 1% in the femoral neck, and 5% in the Ward
triangle, while toremifene demonstrated a slight decrease (0.3%-
0.9%) in BMD (P ¼ nonsigniﬁcant). Erkkola et al. also evaluated
BMD changes during 5 years of treatment with toremifene 60 mg
daily in pre- and postmenopausal women (n ¼ 259).53 Mean
changes in BMD in the lumbar spine, femoral neck, and Ward
triangle were positive but not statistically different from BMD
changes in the placebo group throughout the treatment period.53
Summary
Toremifene citrate was developed more than 20 years ago with
the goal of achieving efﬁcacy similar to that of tamoxifen with animproved safety proﬁle Three pivotal clinical studies demonstrated
toremifene efﬁcacy and safety comparable to that of tamoxifen in
postmenopausal women with ERþ or ER unknown metastatic
breast cancer. More recent data with toremifene should stimulate
further research. Outstanding issues include: i) reasonably
convincing phase III data and a meta-analysis suggesting similar
efﬁcacy and safety for adjuvant toremifene compared with tamox-
ifen in postmenopausal HRþ breast cancer34,36-38,63; ii) suggestions
from a comparative trial that toremifene and letrozole showed
similar efﬁcacy as ﬁrst-line therapy for postmenopausal patients with
hormone receptor-positive metastatic breast cancer39; iii) conﬂicting
data in the ATAC trial, which showed potential antagonism be-
tween anastrozole and tamoxifen in combination vs. anastrozole
alone, while the combination of toremifene and a different aro-
matase inhibitor, atamestane, showed results equivalent to those of
letrozole40; iv) suggestions that higher than standard doses of
toremifene might be effective in patients for whom aromatase
inhibitors have failed or even in patients progressing on tamoxi-
fen42-44,46; v) a controversial study from China suggesting that
toremifene use in premenopausal patients in the adjuvant setting (in
the absence of meaningful clinical trial data in premenopausal
women) was not inferior to tamoxifen use.51 Finally, despite clinical
controversies surrounding alterations in CTP2D6 on tamoxifen
outcomes, it is clear that the toremifene mechanism of action is
independent of CYP2D6.20,27,29
Conclusion
Toremifene is a viable alternative to tamoxifen in post-
menopausal patients with ERþ metastatic breast cancer. Newer
data, which would need to be conﬁrmed with additional studies,
suggest other potentially useful roles for this compound.Clinical Breast Cancer February 2014 - 7
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